Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | PRSS1 | P07477 | 8/20 | 0.53 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.52 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.52 |
| ▸ | F10 | P00742 | 1/20 | 0.52 |
| ▸ | F2 | P00734 | 8/20 | 0.52 |
| ▸ | TMPRSS6 | Q8IU80 | 3/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | PLG | P00747 | 1/20 | 0.48 |
| ▸ | C1S | P09871 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7984063 | 1.00 | RAB9A (0.54) | RAB9APRSS1PRSS2PRSS3F10 | |
| SCHEMBL7986806 | 1.00 | RAB9A (0.54) | RAB9APRSS1PRSS2PRSS3F10 | |
| SCHEMBL7389439 | 0.99 | RAB9A (0.55) | RAB9APRSS1PRSS2PRSS3F10 | |
| SCHEMBL7982625 | 0.97 | RAB9A (0.55) | RAB9APRSS1PRSS2PRSS3F10 | |
| SCHEMBL7423694 | 0.95 | RAB9A (0.56) | RAB9APRSS1PRSS2PRSS3F10 | |
| SCHEMBL10035190 | 0.91 | HTT (0.58) | RAB9APRSS1PRSS2PRSS3F10 | |
| SCHEMBL7538755 | 0.90 | PRSS1 (0.59) | RAB9APRSS1PRSS2PRSS3F10 | |
| SCHEMBL7986314 | 0.90 | F10 (0.53) | RAB9APRSS1PRSS2PRSS3F10 | |
| SCHEMBL7986856 | 0.88 | HTT (0.57) | RAB9AF10F2TMPRSS6HTT | |
| SCHEMBL7989750 | 0.86 | PRMT1 (0.60) | RAB9APRSS1F10F2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230255969-A1 | TARGETING IMMUNE PATHOLOGIES INDUCED BY HIGHLY PATHOGENIC CORONAVIRUSES | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2023-08-17 | — | — | US | claimed |
| EP-4185286-A1 | TARGETING IMMUNE PATHOLOGIES INDUCED BY HIGHLY PATHOGENIC CORONAVIRUSES | National University of Singapore (SG) | 2023-05-31 | — | — | EP | claimed |
| WO-2022019828-A1 | TARGETING IMMUNE PATHOLOGIES INDUCED BY HIGHLY PATHOGENIC CORONAVIRUSES | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2022-01-27 | — | — | WO | claimed |
| US-6221914-B1 | ANTIINFLAMMATORY AGENTS | ARRAY BIOPHARMA INC. | 2001-04-24 | — | — | US | claimed |
| US-12551475-B2 | Methods and compositions for treating RNA viral infections | MODEL MEDICINES, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4667008-A2 | METHODS AND COMPOSITIONS FOR TREATING RNA VIRAL INFECTIONS | Model Medicines, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250025454-A1 | USE OF PIPENDOXIFENE TO TREAT SARS-COV-2 INFECTION | MODEL MEDICINES INC (US) | 2025-01-23 | — | — | US | disclosed |
| US-20240082228-A1 | SARS-COV-2 THERAPEUTICS | MODEL MEDICINES INC (US) | 2024-03-14 | — | — | US | disclosed |
| EP-4281180-A1 | SARS-COV-2 THERAPEUTICS | Model Medicines, Inc. (US) | 2023-11-29 | — | — | EP | disclosed |
| US-20230346792-A1 | COMPOSITIONS AND METHODS FOR TREATING LUNG INFLAMMATION | HOTH THERAPEUTICS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230255969-A1 | TARGETING IMMUNE PATHOLOGIES INDUCED BY HIGHLY PATHOGENIC CORONAVIRUSES | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2023-08-17 | — | — | US | disclosed |
| US-20230248712-A1 | METHODS AND COMPOSITIONS FOR TREATING RNA VIRAL INFECTIONS | MODEL MEDICINES, INC. | 2023-08-10 | — | — | US | disclosed |
| EP-4185286-A1 | TARGETING IMMUNE PATHOLOGIES INDUCED BY HIGHLY PATHOGENIC CORONAVIRUSES | National University of Singapore (SG) | 2023-05-31 | — | — | EP | disclosed |
| EP-4157448-A1 | METHODS AND COMPOSITIONS FOR TREATING RNA VIRAL INFECTIONS | Model Medicines, Inc. (US) | 2023-04-05 | — | — | EP | disclosed |
| WO-2022159763-A1 | SARS-COV-2 THERAPEUTICS | MODEL MEDICINES, INC. (US) | 2022-07-28 | — | — | WO | disclosed |
| WO-2022019828-A1 | TARGETING IMMUNE PATHOLOGIES INDUCED BY HIGHLY PATHOGENIC CORONAVIRUSES | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2022-01-27 | — | — | WO | disclosed |
| US-6221914-B1 | ANTIINFLAMMATORY AGENTS | ARRAY BIOPHARMA INC. | 2001-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12551475-B2 | Methods and compositions for treating RNA viral infections | SARS1, EIF2AK2, SNRPE | RAB9A 1447/4885PRSS1 417/4885PRSS2 228/4885 |
| US-20250025454-A1 | USE OF PIPENDOXIFENE TO TREAT SARS-COV-2 INFECTION | EIF2AK2, ACE2, SARS1 | RAB9A 1238/4885PRSS1 554/4885PRSS2 157/4885 |
| US-20230346792-A1 | COMPOSITIONS AND METHODS FOR TREATING LUNG INFLAMMATION | ACE2, TMPRSS2, VIPR1 | RAB9A 4250/4885PRSS1 67/4885PRSS2 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.